他莫昔芬治疗卵巢癌的II期研究。
A phase II study of tamoxifen in ovarian cancer.
作者信息
Slevin M L, Harvey V J, Osborne R J, Shepherd J H, Williams C J, Mead G M
出版信息
Eur J Cancer Clin Oncol. 1986 Mar;22(3):309-12. doi: 10.1016/0277-5379(86)90396-2.
PMID:3709599
Abstract
A phase II study of tamoxifen was conducted in 22 patients with stage III and IV ovarian cancer who had failed chemotherapy and who had evaluable disease. Tamoxifen was administered at a dose of 20 mg twice daily continuously until evidence of progression. Twenty-one patients had progression of disease within 3 months and one patient had stable disease for 6 months. There were no objective responses to this treatment.
摘要
对22例III期和IV期卵巢癌患者进行了他莫昔芬的II期研究，这些患者化疗失败且有可评估的疾病。他莫昔芬以每日两次、每次20毫克的剂量持续给药，直至出现疾病进展的证据。21例患者在3个月内出现疾病进展，1例患者疾病稳定6个月。该治疗未观察到客观缓解。
Zotero 插件